Cargando…
Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1
Tamoxifen resistance is accountable for relapse in many ER-positive breast cancer patients. Most of these recurrent patients receive chemotherapy, but their chemosensitivity is unknown. Here, we report that tamoxifen-resistant breast cancer cells express significantly more BARD1 and BRCA1, leading t...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913295/ https://www.ncbi.nlm.nih.gov/pubmed/29686231 http://dx.doi.org/10.1038/s41467-018-03951-0 |
_version_ | 1783316511065112576 |
---|---|
author | Zhu, Yinghua Liu, Yujie Zhang, Chao Chu, Junjun Wu, Yanqing Li, Yudong Liu, Jieqiong Li, Qian Li, Shunying Shi, Qianfeng Jin, Liang Zhao, Jianli Yin, Dong Efroni, Sol Su, Fengxi Yao, Herui Song, Erwei Liu, Qiang |
author_facet | Zhu, Yinghua Liu, Yujie Zhang, Chao Chu, Junjun Wu, Yanqing Li, Yudong Liu, Jieqiong Li, Qian Li, Shunying Shi, Qianfeng Jin, Liang Zhao, Jianli Yin, Dong Efroni, Sol Su, Fengxi Yao, Herui Song, Erwei Liu, Qiang |
author_sort | Zhu, Yinghua |
collection | PubMed |
description | Tamoxifen resistance is accountable for relapse in many ER-positive breast cancer patients. Most of these recurrent patients receive chemotherapy, but their chemosensitivity is unknown. Here, we report that tamoxifen-resistant breast cancer cells express significantly more BARD1 and BRCA1, leading to resistance to DNA-damaging chemotherapy including cisplatin and adriamycin, but not to paclitaxel. Silencing BARD1 or BRCA1 expression or inhibition of BRCA1 phosphorylation by Dinaciclib restores the sensitivity to cisplatin in tamoxifen-resistant cells. Furthermore, we show that activated PI3K/AKT pathway is responsible for the upregulation of BARD1 and BRCA1. PI3K inhibitors decrease the expression of BARD1 and BRCA1 in tamoxifen-resistant cells and re-sensitize them to cisplatin both in vitro and in vivo. Higher BARD1 and BRCA1 expression is associated with worse prognosis of early breast cancer patients, especially the ones that received radiotherapy, indicating the potential use of PI3K inhibitors to reverse chemoresistance and radioresistance in ER-positive breast cancer patients. |
format | Online Article Text |
id | pubmed-5913295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-59132952018-04-25 Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 Zhu, Yinghua Liu, Yujie Zhang, Chao Chu, Junjun Wu, Yanqing Li, Yudong Liu, Jieqiong Li, Qian Li, Shunying Shi, Qianfeng Jin, Liang Zhao, Jianli Yin, Dong Efroni, Sol Su, Fengxi Yao, Herui Song, Erwei Liu, Qiang Nat Commun Article Tamoxifen resistance is accountable for relapse in many ER-positive breast cancer patients. Most of these recurrent patients receive chemotherapy, but their chemosensitivity is unknown. Here, we report that tamoxifen-resistant breast cancer cells express significantly more BARD1 and BRCA1, leading to resistance to DNA-damaging chemotherapy including cisplatin and adriamycin, but not to paclitaxel. Silencing BARD1 or BRCA1 expression or inhibition of BRCA1 phosphorylation by Dinaciclib restores the sensitivity to cisplatin in tamoxifen-resistant cells. Furthermore, we show that activated PI3K/AKT pathway is responsible for the upregulation of BARD1 and BRCA1. PI3K inhibitors decrease the expression of BARD1 and BRCA1 in tamoxifen-resistant cells and re-sensitize them to cisplatin both in vitro and in vivo. Higher BARD1 and BRCA1 expression is associated with worse prognosis of early breast cancer patients, especially the ones that received radiotherapy, indicating the potential use of PI3K inhibitors to reverse chemoresistance and radioresistance in ER-positive breast cancer patients. Nature Publishing Group UK 2018-04-23 /pmc/articles/PMC5913295/ /pubmed/29686231 http://dx.doi.org/10.1038/s41467-018-03951-0 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Zhu, Yinghua Liu, Yujie Zhang, Chao Chu, Junjun Wu, Yanqing Li, Yudong Liu, Jieqiong Li, Qian Li, Shunying Shi, Qianfeng Jin, Liang Zhao, Jianli Yin, Dong Efroni, Sol Su, Fengxi Yao, Herui Song, Erwei Liu, Qiang Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 |
title | Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 |
title_full | Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 |
title_fullStr | Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 |
title_full_unstemmed | Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 |
title_short | Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1 |
title_sort | tamoxifen-resistant breast cancer cells are resistant to dna-damaging chemotherapy because of upregulated bard1 and brca1 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913295/ https://www.ncbi.nlm.nih.gov/pubmed/29686231 http://dx.doi.org/10.1038/s41467-018-03951-0 |
work_keys_str_mv | AT zhuyinghua tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT liuyujie tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT zhangchao tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT chujunjun tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT wuyanqing tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT liyudong tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT liujieqiong tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT liqian tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT lishunying tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT shiqianfeng tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT jinliang tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT zhaojianli tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT yindong tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT efronisol tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT sufengxi tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT yaoherui tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT songerwei tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 AT liuqiang tamoxifenresistantbreastcancercellsareresistanttodnadamagingchemotherapybecauseofupregulatedbard1andbrca1 |